China's National Medical Products Administration accepted the application of Zhejiang Huahai Pharmaceutical's (SHA:600521) unit, Shanghai Huaota Pharmaceutical, for the domestic production and marketing authorization of the risankizumab injection.
The drug is used for the treatment of acute flares in adults with generalized pustular psoriasis, according to a Shanghai bourse filing on Friday.
The pharmaceutical company invested 226.8 million yuan in the research and development of the drug.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments